Ikonisys S.A. (ALIKO.PA)
| Previous close | 1.4900 |
| Open | 1.4900 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 1.4900 - 1.4900 |
| 52-week range | 1.1400 - 1.8000 |
| Volume | |
| Avg. volume | 7,458 |
| Market cap | 15.573M |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.30 |
- Business Wire
Ikonisys: Hospitex to Obtain International Patent for the BLOCKfast Cyto-Inclusion Kit
PARIS, May 15, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces that Hospitex International has obtained the international patent for the BLOCKfast cytoinclusion kit.
- Business Wire
Ikonisys Announces the Postponement of the Publication of Its Annual Financial Report
PARIS, April 30, 2024--Regulatory News: Ikonisys SA (ISIN Code: FR00140048X2 / Ticker: ALIKO) (Paris:ALIKO), a company specializing in the early and accurate detection of cancer with a unique and fully-automated solution for medical diagnostic labs, announces that the publication of its 2023 annual financial report will be made by May, 27 and not on April, 30.
- Business Wire
Ikonisys: Hospitex International to Partner With Allianz Value for First Large-Scale Screening Program Dedicated to Urinary Tract Oncology Diagnostics in Italy
PARIS, February 29, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces the collaboration of Hospitex International with Allianz Value, a company belonging to Allianz S.p.A. dedicated to both companies’ welfare solutions and home health services and health prevention, for the deployment of the first large-scale screenin
